Use this link to cite:
https://hdl.handle.net/2183/46018 Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery: a multicentric experience in Spain
Loading...
Identifiers
Publication date
Authors
López-Vilella, Raquel
López-Granados, Amador
Mirabet, Sonia
Díez-López, Carles
Barge-Caballero, Eduardo
Segovia Cubero, Javier
González-Vílchez, Francisco
Rangel Sousa, Diego
Blasco-Peiró, Teresa
Advisors
Other responsabilities
Journal Title
Bibliographic citation
Crespo-Leiro MG, López-Vilella R, López Granados A, Mirabet-Pérez S, Díez-López C, Barge-Caballero E, Segovia-Cubero J, González-Vilchez F, Rangel-Sousa D, Blasco-Peiró T, de la Fuente-Galán L, Díaz-Molina B, Zatarain-Nicolás E, Carrasco Ávalos F, Almenar-Bonet L. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery: a multicentric experience in Spain. Clin Transplant. 2019 Dec;33(12):e13748.
Type of academic work
Academic degree
Abstract
[Abstract]
Background: Anticoagulation in heart transplant (HT) recipients increases the risk of hemorrhagic complications, so correct reversal of anticoagulation is needed. Dabigatran, a direct thrombin inhibitor, is increasingly used for anticoagulation in patients with non-valvular atrial fibrillation (NVAF) whose effect can be reversed by idarucizumab.
Aim: To present a nationwide experience using idarucizumab for the urgent reversal of dabigatran before HT.
Methods: Multicenter observational study in 12 Spanish centers to analyze the clinical outcomes after using idarucizumab before HT surgery.
Results: Fifty-three patients were included (81.1% male). 7.5% required re-operation in the immediate postoperative period to control bleeding and 66% transfusion of blood products. Median length of stay in the intensive care unit was 6 days and total hospital stay 24 days. 30-day survival was 92.4%. There were four deaths in the first month, all in the first 5 days post-HT. Only in one patient (transplanted due to a congenital heart disease, after sternotomy) who had surgical problems and right ventricular failure post-HT death was associated with bleeding.
Conclusions: These results may support the use of dabigatran as an alternative to vitamin K antagonists in patients listed for HT requiring anticoagulation due to NVAF. More studies are needed to reaffirm these observations.
Description
Case report
Keywords
Editor version
Rights
This is the peer reviewed version of the article, which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.